NRGN and PRKCA |
neurogranin (protein kinase C substrate, RC3) |
protein kinase C, alpha |
|
- Ca-dependent events
- Signaling by GPCR
- CaM pathway
- Signaling by FGFR in disease
- Phospholipase C-mediated cascade
- Integration of energy metabolism
- Mitotic Prophase
- Signaling by Wnt
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Regulation of KIT signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- Response to elevated platelet cytosolic Ca2+
- G alpha (z) signalling events
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Signaling by PDGF
- Calmodulin induced events
- DAP12 interactions
- Regulation of mRNA stability by proteins that bind AU-rich elements
- Opioid Signalling
- Diseases associated with visual transduction
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- Signaling by EGFR
- Syndecan interactions
- GPCR downstream signaling
- Signaling by VEGF
- Calmodulin induced events
- Downstream signal transduction
- WNT5A-dependent internalization of FZD4
- Signaling by EGFR in Cancer
- Platelet activation, signaling and aggregation
- PCP/CE pathway
- Transmission across Chemical Synapses
- Trafficking of GluR2-containing AMPA receptors
- Nuclear Envelope Breakdown
- HuR stabilizes mRNA
- DAG and IP3 signaling
- M Phase
- VEGFA-VEGFR2 Pathway
- CaM pathway
- Inactivation, recovery and regulation of the phototransduction cascade
- EGFR Transactivation by Gastrin
- VEGFR2 mediated cell proliferation
- Downstream signaling of activated FGFR
- The phototransduction cascade
- Disinhibition of SNARE formation
- Innate Immune System
- Signalling by NGF
- PLC beta mediated events
- Regulation of insulin secretion
- Depolymerisation of the Nuclear Lamina
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- G-protein mediated events
- Non-integrin membrane-ECM interactions
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Trafficking of AMPA receptors
- Cell Cycle, Mitotic
- Signaling by FGFR
- beta-catenin independent WNT signaling
- Acetylcholine regulates insulin secretion
- Visual phototransduction
- Ca2+ pathway
- PLC-gamma1 signalling
- Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
|
|
- Phosphatidylserine
- Vitamin E
- Ingenol Mebutate
- Ellagic Acid
|
|
|
NRGN and PRKCB |
neurogranin (protein kinase C substrate, RC3) |
protein kinase C, beta |
|
- Signaling by the B Cell Receptor (BCR)
- Trafficking of GluR2-containing AMPA receptors
- Signaling by GPCR
- Mitotic Prophase
- Nuclear Envelope Breakdown
- Signaling by Wnt
- VEGFA-VEGFR2 Pathway
- M Phase
- Downstream signaling events of B Cell Receptor (BCR)
- VEGFR2 mediated cell proliferation
- Response to elevated platelet cytosolic Ca2+
- G alpha (z) signalling events
- Disinhibition of SNARE formation
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Depolymerisation of the Nuclear Lamina
- Trafficking of AMPA receptors
- Cell Cycle, Mitotic
- beta-catenin independent WNT signaling
- GPCR downstream signaling
- Signaling by VEGF
- Activation of NF-kappaB in B cells
- WNT5A-dependent internalization of FZD4
- Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
- Platelet activation, signaling and aggregation
- PCP/CE pathway
- Adaptive Immune System
- Transmission across Chemical Synapses
|
|
- Vitamin E
- O-Phosphoethanolamine
- Ellagic Acid
|
|
|
NRGN and PRKCG |
neurogranin (protein kinase C substrate, RC3) |
protein kinase C, gamma |
|
- Signaling by GPCR
- Ca-dependent events
- CaM pathway
- Phospholipase C-mediated cascade
- Signaling by FGFR in disease
- Signaling by Wnt
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- DAP12 signaling
- Response to elevated platelet cytosolic Ca2+
- G alpha (z) signalling events
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Signaling by PDGF
- Calmodulin induced events
- DAP12 interactions
- Opioid Signalling
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- Signaling by EGFR
- GPCR downstream signaling
- Downstream signal transduction
- Calmodulin induced events
- WNT5A-dependent internalization of FZD4
- Signaling by EGFR in Cancer
- Platelet activation, signaling and aggregation
- PCP/CE pathway
- Transmission across Chemical Synapses
- Trafficking of GluR2-containing AMPA receptors
- DAG and IP3 signaling
- CaM pathway
- Downstream signaling of activated FGFR
- Disinhibition of SNARE formation
- Innate Immune System
- Signalling by NGF
- PLC beta mediated events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- G-protein mediated events
- NGF signalling via TRKA from the plasma membrane
- Trafficking of AMPA receptors
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- beta-catenin independent WNT signaling
- PLC-gamma1 signalling
- Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
|
|
|
|
|
NTF3 and NTRK3 |
neurotrophin 3 |
neurotrophic tyrosine kinase, receptor, type 3 |
|
|
|
|
|
|
NTRK3 and SHC1 |
neurotrophic tyrosine kinase, receptor, type 3 |
SHC (Src homology 2 domain containing) transforming protein 1 |
|
- Signaling by GPCR
- Signaling by EGFRvIII in Cancer
- Platelet Aggregation (Plug Formation)
- SHC1 events in ERBB2 signaling
- IRE1alpha activates chaperones
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- SHC-mediated signalling
- G-protein beta:gamma signalling
- SHC-related events triggered by IGF1R
- Signaling by ERBB4
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- GPCR downstream signaling
- SHC1 events in ERBB4 signaling
- Signalling to RAS
- Signaling by EGFR in Cancer
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Signalling to ERKs
- IGF1R signaling cascade
- XBP1(S) activates chaperone genes
- G beta:gamma signalling through PI3Kgamma
- Unfolded Protein Response (UPR)
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- SHC-mediated signalling
- Integrin alphaIIb beta3 signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- SHC-related events
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- SHC1 events in EGFR signaling
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Constitutive Signaling by EGFRvIII
- SHC activation
|
|
|
|
|
NTRK3 and FRS2 |
neurotrophic tyrosine kinase, receptor, type 3 |
fibroblast growth factor receptor substrate 2 |
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- PI-3K cascade
- PI3K Cascade
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by FGFR mutants
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Frs2-mediated activation
- Adaptive Immune System
- Signalling to ERKs
- Prolonged ERK activation events
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- IRS-related events triggered by IGF1R
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- IRS-mediated signalling
- FRS2-mediated cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- PI3K Cascade
|
|
|
|
|
NTRK3 and RASGRF1 |
neurotrophic tyrosine kinase, receptor, type 3 |
Ras protein-specific guanine nucleotide-releasing factor 1 |
|
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- CREB phosphorylation through the activation of Ras
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Transmission across Chemical Synapses
- Post NMDA receptor activation events
- Ras activation uopn Ca2+ infux through NMDA receptor
|
|
|
|
|
NTRK3 and DOK5 |
neurotrophic tyrosine kinase, receptor, type 3 |
docking protein 5 |
|
|
|
|
|
|
NTRK3 and PTPN1 |
neurotrophic tyrosine kinase, receptor, type 3 |
protein tyrosine phosphatase, non-receptor type 1 |
|
- Interferon gamma signaling
- Regulation of IFNA signaling
- Interferon Signaling
- Integrin alphaIIb beta3 signaling
- Cytokine Signaling in Immune system
- Interferon alpha/beta signaling
- Platelet activation, signaling and aggregation
- Platelet Aggregation (Plug Formation)
- Regulation of IFNG signaling
- Growth hormone receptor signaling
|
|
- Tiludronate
- 3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid
- Double Oxidized Cysteine
- Compound 12, N-Acetyl-4-[(Carboxycarbonyl)(2-Carboxyphenyl)Amino]-N-Pentyl-1-Napthylalaniamide
- Compound 9
- 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid
- 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide
- [[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid,
- 2-{4-[(2s)-2-[({[(1s)-1-Carboxy-2-Phenylethyl]Amino}Carbonyl)Amino]-3-Oxo-3-(Pentylamino)Propyl]Phenoxy}Malonic Acid
- Compound 19
- Sp7343-Sp7964
- 2-(Oxalyl-Amino)-Benzoic Acid
- {[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid)
- Novo Nordisk a/S Compound
- N-[4-(2-{2-[3-(2-Bromo-Acetylamino)-Propionylamino]-3-Hydroxy-Propionylamino}-Ethyl)-Phenyl]-Oxalamic Acid
- 7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid
- PNU177836
- 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid
- {[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid
- 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide
- 4-Benzoylamino-4-{1-{1-Carbamoyl-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethylcarbamoyl}-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethylcarbamoyl}-Butyric Acid
- N-{1-[5-(1-Carbamoyl-2-Mercapto-Ethylcarbamoyl)-Pentylcarbamoyl]-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethyl}-3-{2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Acetylamino}-Succinamic Acid
- Cysteinesulfonic Acid
- 2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid
- 4-Carbamoyl-4-{[6-(Difluoro-Phosphono-Methyl)-Naphthalene-2-Carbonyl]-Amino}-Butyric Acid
- Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid
- 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid
- N-(Allyloxycarbonyl)-4-[N-(Carboxy-Formyl)-2-(Benzoic Acid)-Amino]-L-Phenylalaninyl-Amino-Butyloxy-(6-Hydroxy-Benzoic Acid Methyl Ester)
- 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide
- [(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid
- {4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid
- 2-(Carboxymethoxy)-5-[(2s)-2-({(2s)-2-[(3-Carboxypropanoyl)Amino] -3-Phenylpropanoyl}Amino)-3-Oxo-3-(Pentylamino)Propyl]Benzoic Acid
- 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID
- 4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID
- 3(S)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID TERT-BUTYL ESTER
- 4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID
- 5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE
- 4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID
- [{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid
- 5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID
- 2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID
- 3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID
- 4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN
- N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE
- 3(R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID TERT-BUTYL ESTER
- 5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE
- 5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID
- ISOTHIAZOLIDINONE ANALOG
- 4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid
- PARA-(BENZOYL)-PHENYLALANINE
- 6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID
- (3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER
- 5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE
- 1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE
- (4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid
|
|
|
NTRK3 and IRAK3 |
neurotrophic tyrosine kinase, receptor, type 3 |
interleukin-1 receptor-associated kinase 3 |
|
- Toll Like Receptor 2 (TLR2) Cascade
- Toll Like Receptor TLR1:TLR2 Cascade
- Activated TLR4 signalling
- Signaling by Interleukins
- Toll-Like Receptors Cascades
- Toll Like Receptor 4 (TLR4) Cascade
- MyD88:Mal cascade initiated on plasma membrane
- Cytokine Signaling in Immune system
- Interleukin-1 signaling
- Toll Like Receptor TLR6:TLR2 Cascade
- Innate Immune System
|
|
|
|
|
NTRK3 and SQSTM1 |
neurotrophic tyrosine kinase, receptor, type 3 |
sequestosome 1 |
|
- Signaling by Interleukins
- Signalling by NGF
- NF-kB is activated and signals survival
- p75NTR recruits signalling complexes
- Cell death signalling via NRAGE, NRIF and NADE
- NRIF signals cell death from the nucleus
- p75NTR signals via NF-kB
- Cytokine Signaling in Immune system
- Interleukin-1 signaling
- p75 NTR receptor-mediated signalling
|
|
|
|
|
NTRK3 and DYNLL1 |
neurotrophic tyrosine kinase, receptor, type 3 |
dynein, light chain, LC8-type 1 |
|
- Organelle biogenesis and maintenance
- Activation of BH3-only proteins
- Assembly of the primary cilium
- G2/M Transition
- Anchoring of the basal body to the plasma membrane
- Regulation of PLK1 Activity at G2/M Transition
- Cell Cycle, Mitotic
- Intraflagellar transport
- Loss of proteins required for interphase microtubule organization from the centrosome
- Activation of BIM and translocation to mitochondria
- Loss of Nlp from mitotic centrosomes
- MHC class II antigen presentation
- Programmed Cell Death
- Centrosome maturation
- Mitotic G2-G2/M phases
- Recruitment of mitotic centrosome proteins and complexes
- Adaptive Immune System
- Intrinsic Pathway for Apoptosis
|
|
|
|
|
NTRK3 and KIDINS220 |
neurotrophic tyrosine kinase, receptor, type 3 |
kinase D-interacting substrate, 220kDa |
|
- ARMS-mediated activation
- Signalling to ERKs
- Signalling by NGF
- Prolonged ERK activation events
- NGF signalling via TRKA from the plasma membrane
|
|
|
|
|
NTRK3 and PLCG1 |
neurotrophic tyrosine kinase, receptor, type 3 |
phospholipase C, gamma 1 |
|
- Signaling by the B Cell Receptor (BCR)
- Phospholipase C-mediated cascade
- Signaling by FGFR in disease
- FCERI mediated MAPK activation
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- DAP12 signaling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Synthesis of IP3 and IP4 in the cytosol
- Signaling by FGFR1 mutants
- Role of phospholipids in phagocytosis
- Fcgamma receptor (FCGR) dependent phagocytosis
- Signaling by PDGF
- DAP12 interactions
- Inositol phosphate metabolism
- Antiviral mechanism by IFN-stimulated genes
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- Signaling by EGFR
- TCR signaling
- Signaling by VEGF
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Signaling by FGFR mutants
- Frs2-mediated activation
- Adaptive Immune System
- Signalling to ERKs
- Prolonged ERK activation events
- Axon guidance
- DAG and IP3 signaling
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated cell proliferation
- Downstream signaling of activated FGFR
- Netrin-1 signaling
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- Signalling by NGF
- Generation of second messenger molecules
- ISG15 antiviral mechanism
- Interferon Signaling
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- PECAM1 interactions
- Cell surface interactions at the vascular wall
- Role of second messengers in netrin-1 signaling
- PLC-gamma1 signalling
- FCERI mediated Ca+2 mobilization
- Constitutive Signaling by EGFRvIII
- Signaling by FGFR1 fusion mutants
|
|
|
|
|
NTRK3 and MAPK1 |
neurotrophic tyrosine kinase, receptor, type 3 |
mitogen-activated protein kinase 1 |
|
- phospho-PLA2 pathway
- Ca-dependent events
- Signaling by FGFR in disease
- Cellular Senescence
- ERKs are inactivated
- CREB phosphorylation through the activation of Ras
- Signaling by EGFRvIII in Cancer
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Fcgamma receptor (FCGR) dependent phagocytosis
- SHC-mediated signalling
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Regulation of actin dynamics for phagocytic cup formation
- TRIF-mediated TLR3/TLR4 signaling
- Senescence-Associated Secretory Phenotype (SASP)
- Signaling by VEGF
- Signalling to RAS
- Downstream signal transduction
- Toll Like Receptor 3 (TLR3) Cascade
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Transmission across Chemical Synapses
- Axon guidance
- IRS-mediated signalling
- L1CAM interactions
- Oncogene Induced Senescence
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- RSK activation
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- NCAM signaling for neurite out-growth
- Signalling to p38 via RIT and RIN
- RAF/MAP kinase cascade
- Innate Immune System
- Signaling by Insulin receptor
- ERKs are inactivated
- Signal transduction by L1
- Insulin receptor signalling cascade
- PLC beta mediated events
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- SHC-related events
- G-protein mediated events
- Signaling by FGFR
- Thrombin signalling through proteinase activated receptors (PARs)
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- ERK/MAPK targets
- MAPK targets/ Nuclear events mediated by MAP kinases
- Signaling by GPCR
- Mitotic Prophase
- Golgi Cisternae Pericentriolar Stack Reorganization
- FCERI mediated MAPK activation
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- ERK/MAPK targets
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- Opioid Signalling
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Signaling by Leptin
- Growth hormone receptor signaling
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Recycling pathway of L1
- M Phase
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- Activation of the AP-1 family of transcription factors
- MyD88 cascade initiated on plasma membrane
- ERK activation
- Downstream signaling of activated FGFR
- Advanced glycosylation endproduct receptor signaling
- Post NMDA receptor activation events
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- Cellular response to heat stress
- Regulation of HSF1-mediated heat shock response
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell Cycle, Mitotic
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- Oxidative Stress Induced Senescence
- ERK2 activation
- Nuclear Events (kinase and transcription factor activation)
|
|
- Isoproterenol
- Arsenic trioxide
- Olomoucine
- Phosphonothreonine
- Purvalanol
- SB220025
- N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
- (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
- 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
- (1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
- 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
|
|
|
NTRK3 and MAPK3 |
neurotrophic tyrosine kinase, receptor, type 3 |
mitogen-activated protein kinase 3 |
|
- Signaling by FGFR in disease
- RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
- Cellular Senescence
- ERKs are inactivated
- Signaling by EGFRvIII in Cancer
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Fcgamma receptor (FCGR) dependent phagocytosis
- SHC-mediated signalling
- Regulation of actin dynamics for phagocytic cup formation
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- Senescence-Associated Secretory Phenotype (SASP)
- ERK1 activation
- Signaling by VEGF
- Downstream signal transduction
- Toll Like Receptor 3 (TLR3) Cascade
- Signalling to RAS
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Axon guidance
- IRS-mediated signalling
- L1CAM interactions
- Oncogene Induced Senescence
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- ERKs are inactivated
- Signal transduction by L1
- Insulin receptor signalling cascade
- ISG15 antiviral mechanism
- Interferon Signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- Signaling by FGFR
- Thrombin signalling through proteinase activated receptors (PARs)
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- ERK/MAPK targets
- MAPK targets/ Nuclear events mediated by MAP kinases
- Signaling by GPCR
- FCERI mediated MAPK activation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- ERK/MAPK targets
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Antiviral mechanism by IFN-stimulated genes
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Growth hormone receptor signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- RNA Polymerase I Promoter Clearance
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- Activation of the AP-1 family of transcription factors
- MyD88 cascade initiated on plasma membrane
- ERK activation
- Downstream signaling of activated FGFR
- Advanced glycosylation endproduct receptor signaling
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- RNA Polymerase I Transcription
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- Cellular response to heat stress
- Regulation of HSF1-mediated heat shock response
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- Oxidative Stress Induced Senescence
- RNA Polymerase I Promoter Opening
- Nuclear Events (kinase and transcription factor activation)
|
|
- Sulindac
- Arsenic trioxide
- Purvalanol
- 5-iodotubercidin
|
|
|
NTRK3 and NGFRAP1 |
neurotrophic tyrosine kinase, receptor, type 3 |
nerve growth factor receptor (TNFRSF16) associated protein 1 |
|
- Signalling by NGF
- Cell death signalling via NRAGE, NRIF and NADE
- p75 NTR receptor-mediated signalling
- NADE modulates death signalling
|
|
|
|
|
NTRK3 and SHC2 |
neurotrophic tyrosine kinase, receptor, type 3 |
SHC (Src homology 2 domain containing) transforming protein 2 |
|
- Signalling to ERKs
- Signalling by NGF
- Insulin receptor signalling cascade
- SHC-mediated signalling
- SHC-related events triggered by IGF1R
- SHC-related events
- NGF signalling via TRKA from the plasma membrane
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- Signal attenuation
- Signaling by VEGF
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Signalling to RAS
- SHC-mediated signalling
- Signaling by Insulin receptor
|
|
|
|
|
ROR2 and IKBKG |
receptor tyrosine kinase-like orphan receptor 2 |
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma |
- WNT5A-dependent internalization of FZD2, FZD5 and ROR2
- Signaling by Wnt
- PCP/CE pathway
- beta-catenin independent WNT signaling
|
- Signaling by the B Cell Receptor (BCR)
- Downstream TCR signaling
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- RIP-mediated NFkB activation via ZBP1
- Toll Like Receptor TLR6:TLR2 Cascade
- IRAK1 recruits IKK complex
- Downstream signaling events of B Cell Receptor (BCR)
- Activated TLR4 signalling
- Toll Like Receptor TLR1:TLR2 Cascade
- FCERI mediated NF-kB activation
- MyD88 cascade initiated on plasma membrane
- Toll Like Receptor 5 (TLR5) Cascade
- ZBP1(DAI) mediated induction of type I IFNs
- NOD1/2 Signaling Pathway
- MyD88 dependent cascade initiated on endosome
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- Toll Like Receptor 9 (TLR9) Cascade
- IRAK1 recruits IKK complex
- JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
- Innate Immune System
- activated TAK1 mediates p38 MAPK activation
- TRIF-mediated TLR3/TLR4 signaling
- MAP kinase activation in TLR cascade
- IKK complex recruitment mediated by RIP1
- Cytosolic sensors of pathogen-associated DNA
- Cytokine Signaling in Immune system
- MyD88-independent cascade
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by Interleukins
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- TCR signaling
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- Activation of NF-kappaB in B cells
- Toll Like Receptor 3 (TLR3) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Fc epsilon receptor (FCERI) signaling
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Adaptive Immune System
|
|
|
|
|
ROR2 and PRR20A |
receptor tyrosine kinase-like orphan receptor 2 |
proline rich 20A |
- WNT5A-dependent internalization of FZD2, FZD5 and ROR2
- Signaling by Wnt
- PCP/CE pathway
- beta-catenin independent WNT signaling
|
|
|
|
|
|